These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 2867161)

  • 21. Observations on some properties of a long-acting preparation of propranolol.
    Shanks RG; Neill JD; Leahey WJ; Varma MP
    Clin Sci (Lond); 1979 Dec; 57 Suppl 5():409s-411s. PubMed ID: 540460
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacokinetic investigation of the absorption of oxprenolol from Oros delivery systems in healthy volunteers: comparison of in vivo and in vitro drug release.
    Bradbrook ID; John VA; Morrison PJ; Rogers HJ; Spector RG
    Br J Clin Pharmacol; 1985; 19 Suppl 2(Suppl 2):163S-169S. PubMed ID: 4005118
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Comparison of the effects of oxprenolol and nifedipine on blood pressure at rest and during physical exercise in essential hypertension].
    Gambini G; Pizzuti C; Valori C
    Clin Ter; 1988 Feb; 124(3):203-10. PubMed ID: 2974332
    [No Abstract]   [Full Text] [Related]  

  • 24. Effect of oxprenolol on heart rate.
    Hedges A; Turner P
    Br Med J; 1973 Feb; 1(5850):422. PubMed ID: 4691086
    [No Abstract]   [Full Text] [Related]  

  • 25. Slow release oxprenolol in angina pectoris: study comparing oxprenolol, once daily, with propranolol, four times daily.
    Olowoyeye JO; Thadani U; Parker JO
    Am J Cardiol; 1981 May; 47(5):1123-7. PubMed ID: 7223659
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of oxprenolol and methyldopa in hypertension. A within-patient double-blind trial.
    Barritt DW; Marshall AJ; Heaton S
    Lancet; 1976 Mar; 1(7958):503-5. PubMed ID: 55780
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Reproducibility of oxprenolol plasma concentrations in young female volunteers following oral administration of an oxprenolol Oros dosage form.
    Jack DB; Kendall MJ; Laugher SJ; Smith SR
    Br J Clin Pharmacol; 1985; 19 Suppl 2(Suppl 2):185S-190S. PubMed ID: 4005121
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Relation between plasma concentrations and cardiovascular effects of oral oxprenolol in man.
    Brunner L; Imhof P; Jack D
    Eur J Clin Pharmacol; 1975; 8(1):3-9. PubMed ID: 786674
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of clinical effects of propranolol (Inderal) with once daily slow-release oxprenolol (Slow Trasicor) in angina pectoris.
    Majid PA; de Feijter PJ; Wardeh R; van der Wall EE; Roos JP
    J Int Med Res; 1979; 7(3):194-200. PubMed ID: 378729
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluation of oxprenolol and metoprolol Oros systems in the dog: comparison of in vivo and in vitro drug release, and of drug absorption from duodenal and colonic infusion sites.
    Fara JW; Myrback RE; Swanson DR
    Br J Clin Pharmacol; 1985; 19 Suppl 2(Suppl 2):91S-95S. PubMed ID: 4005134
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The pharmacokinetics of oxprenolol following oral and rectal dosing--a comparison of delivery systems and routes of administration.
    Gregg MR; Jack DB; Smith SR; Kendall MJ
    J Clin Pharm Ther; 1987 Apr; 12(2):91-9. PubMed ID: 3584272
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A fixed combination of oxprenolol slow-release and chlorthalidone once daily in treatment of mild to moderate hypertension.
    Muiesan G; Agabiti-Rosei E; Buoninconti R; Carotti A; Fariello R; Innocenti P; Toso M; Valori C; Motolese M
    Int J Clin Pharmacol Ther Toxicol; 1981 Jun; 19(6):249-55. PubMed ID: 7309298
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Concentration-effect relationships for oxprenolol in patients with essential hypertension.
    McInnes GT; Brodie MJ
    Br J Clin Pharmacol; 1988 May; 25(5):539-45. PubMed ID: 3408634
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A multicentre evaluation of sustained release oxprenolol in the management of hypertension in hospital out-patient practice.
    Forrest WA
    J Int Med Res; 1978; 6(2):136-40. PubMed ID: 631415
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Oxprenolol absorption in man after single bolus dosing into two segments of the colon compared with that after oral dosing.
    Antonin KH; Bieck P; Scheurlen M; Jedrychowski M; Malchow H
    Br J Clin Pharmacol; 1985; 19 Suppl 2(Suppl 2):137S-142S. PubMed ID: 4005115
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Heart-rates of surgeons during operations and other clinical activities and their modification by oxprenolol.
    Foster GE; Evans DF; Hardcastle JD
    Lancet; 1978 Jun; 1(8078):1323-5. PubMed ID: 78094
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacokinetic-pharmacodynamic modelling of oxprenolol in man using continuous non-invasive blood pressure monitoring.
    Koopmans R; Oosterhuis B; Karemaker JM; Wemer J; van Boxtel CJ
    Eur J Clin Pharmacol; 1988; 34(4):395-400. PubMed ID: 3402525
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of a slow release formulation of oxprenolol with conventional oxprenolol in the treatment of hypertension.
    O'Brien KP; Stephens EJ
    N Z Med J; 1976 Aug; 84(570):142-4. PubMed ID: 1069924
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A comparison of the effects of the slow release formulations of metoprolol and oxprenolol in hypertension.
    Comerford MB; Besterman EM
    Ann Clin Res; 1982 Feb; 14(1):27-31. PubMed ID: 7137874
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Continuous 24-hour registration of intra-arterial pressure in basal states and during therapy with a fixed slow-release oxprenolol-chlorthalidone combination, administered once a day].
    Fariello R; Alicandri C; Boni E; Montini E; Zaninelli A; Agabiti-Rosei E; Motolese M; Muiesan G
    G Ital Cardiol; 1984 Feb; 14(2):121-6. PubMed ID: 6714549
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.